Jonas Bergh, MD, PhD, FRCP
The European Society for Medical Oncology (ESMO) announced recently that Jonas Bergh, MD, PhD, FRCP, of the Karolinska Institutet in Stockholm, has been awarded the newly established 2019 ESMO Breast Cancer Award at the inaugural ESMO Breast Cancer Congress 2019. The ESMO Breast Cancer Award acknowledges experts who have devoted a major part of their career to breast cancer and have made a special contribution to the discovery and development of education, research, and clinical practice in the field.
Sibylle Loibl, MD, PhD, and Giuseppe Curigliano, MD, PhD, Co-Chairs of the ESMO Breast Cancer Congress, said: “Professor Jonas Bergh has conducted clinical trials with new drugs and individually tailored dosing of chemotherapy. The Swedish Group demonstrated in the first randomized study that 5 years of tamoxifen treatment is better that the previously recommended 2 years. He has been involved in showing the additional value of other drugs, in particular chemotherapy, in breast cancer treatment.”
Dr. Bergh is Cancer Theme Prefect and Director of the Strategic Research Programme in Cancer at the Karolinska Institutet in Stockholm, where he is also a member of the Nobel Assembly and holds the Mimi Althainz’ Professorship in Oncology. Dr. Bergh is also Senior Consultant in Oncology at the Karolinska University Hospital, Acting Chair of the Scientific Council in Oncology/Haematology for the European Medicines Agency, Visiting Professor of Breast Cancer Research at Oxford University, and a fellow of the Royal College of Physicians in London.
Dr. Bergh’s research is mainly focused on breast cancer biology, including tailored breast cancer treatments and the alteration of characteristics during disease progression. ■
